Evidence map›Paper›PMID 39367743›Full record

ArticleClinical genetics2025

Consolidating the Role of Mutated ATP2B2 in Neurodevelopmental and Cerebellar Pathologies.

Antonia M Stehr, Jerica Lenberg, Jennifer Friedman, Dries Dobbelaere, Apolline Imbard, Jonathan Levy, Sarah Donoghue, Nicolas Derive, Radka Stoeva, Paul Gueguen and 1 more

Abstract read
In one paragraph

Article in Clinical genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Antonia M StehrSchool of Medicine and Health, Institute of Human Genetics, Technical University of Munich, Munich, Germany.
Jerica LenbergRady Children's Institute for Genomic Medicine, San Diego, California, USA.
Jennifer FriedmanRady Children's Institute for Genomic Medicine, San Diego, California, USA.
Dries DobbelaereMedical Reference Center for Inherited Metabolic Diseases, Jeanne de Flandre University Hospital, Lille, France.
Apolline ImbardLaboratoire de Biochimie Métabolique, Hôpital Necker-Enfants Malades and Faculty of Pharmacy, Université Paris-Saclay, Paris, France.
Jonathan LevyLaboratoire de Biologie médicale Multisites Seqoia - FMG2025, Paris, France.ORCID 0000-0002-8822-816X
Sarah DonoghueMurdoch Children's Research Institute, Parkville, Australia.
Nicolas DeriveLaboratoire de Biologie médicale Multisites Seqoia - FMG2025, Paris, France.
Radka StoevaService de Génétique Médicale, Centre Hospitalier du Mans, Le Mans, France.
Paul GueguenLaboratoire de Biologie médicale Multisites Seqoia - FMG2025, Paris, France.
Michael ZechSchool of Medicine and Health, Institute of Human Genetics, Technical University of Munich, Munich, Germany.

Funding

EJP RD Joint Transnational Call 2022Else Kröner-Fresenius-Stiftung 2022_EKSE.185Free State of BavariaGerman Federal Ministry of Education and Research (BMBF, Bonn, Germany)German Research Foundation DFG 458949627German Research Foundation ZE 1213/2-1Technical University of Munich - Institute for Advanced Study
6 · The paper itself

Abstract

Plasma membrane calcium ATPases (PMCAs) encoded by ATP2B genes have been implicated in Mendelian diseases with ataxia, dystonia, and intellectual disability. Work to date has shown that ATP2B2 (encoding PMCA2) is required for synaptic function and Purkinje-cell integrity in the cerebellum. A recent case series has linked ATP2B2 to a novel entity, characterized by neurodevelopmental and movement phenotypes, in only seven individuals. We called for collaboration to collect five unpublished families affected by the new rare ATP2B2-related condition. Exome-/genome sequencing-identified genotypes included four likely pathogenic/pathogenic heterozygous de novo missense variants and one dominantly inherited end-truncating frameshift allele. The six affected individuals shared features with the described patients including developmental delay, cognitive disturbances, epilepsy, autistic traits, and motor disorders. Striking cerebellar atrophy was observed in one affected individual. In association with hearing loss and movement abnormalities, we report a recurrent p.(Glu457Lys) substitution, previously documented in a neurologically impaired ATP2B2 mouse mutant. Our study further delineates the mutational spectrum and presentation of a human syndrome caused by ATP2B2 variants, confirming the importance of PMCA2 in neurotypical and cerebellar development.

Indexed as

MutationNeurodevelopmental DisordersPlasma Membrane Calcium-Transporting ATPasesAdolescentAnimalsCerebellumChildChild, PreschoolExome SequencingFemaleGenetic Predisposition to DiseaseHumansIntellectual DisabilityMaleMicePedigreeATP2B2 protein, humanPlasma Membrane Calcium-Transporting ATPasesATP2B2cerebellar atrophydevelopmental delayintellectual disabilitymovement disorderneurodevelopmental disorder

Identifiers

PMID39367743
PMCPMC11608835

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.